US Stock MarketDetailed Quotes
YMAB Y-mAbs Therapeutics
- 10.570
- +0.010+0.09%
Trading Nov 26 10:11 ET
473.42MMarket Cap-19574P/E (TTM)
10.891High10.395Low9.55KVolume10.540Open10.560Pre Close100.71KTurnover0.04%Turnover RatioLossP/E (Static)44.79MShares20.90052wk High5.12P/B286.18MFloat Cap6.05052wk Low--Dividend TTM27.07MShs Float55.215Historical High--Div YieldTTM4.70%Amplitude2.700Historical Low10.549Avg Price1Lot Size
Y-mAbs Therapeutics Key Stats
EPS
According to the latest financial report of Y-mAbs Therapeutics, the latest earnings per share (TTM) for the company is -0.16. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Y-mAbs Therapeutics's free cash flow? The latest report shows it as -10.67M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Y-mAbs Therapeutics shows that the company's current ratio is 3.92, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Y-mAbs Therapeutics, the quick ratio is 3.48, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Y-mAbs Therapeutics? The latest ROE figure is -7.45%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Y-mAbs Therapeutics, the total asset return on investment (ROA) is -5.28%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Y-mAbs Therapeutics's latest financial report to see how their gross margin is doing - currently at 87.82%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Y-mAbs Therapeutics, the net profit margin is -37.91%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data